There was no statistically significant difference between the groups in the RNLF evaluation (p>0.05).Conclusion: Treatment with IV prednisolone had no distinct effect on RNFL
📌 3 Maddede Bu Makale
🎯
Amaç & Hipotez:Objectives: The aim of this study was to investigate the potential impact of intravenous (IV) prednisolone treatment on the retinal nerve fiber layer (RNFL) in multiple sclerosis (MS) patients with optic neuritis (ON).Methods: The demographic features, systemic illnesses, laboratory results, ophthalmological examination findings and RNFL measurements of 28 MS patients who had IV prednisolone treatment for ON and of 24 MS patients with ON that was not treated were retrieved and reviewed retrospectively.Results: Of the 52 patients included in the study, 31 were women and 21 were men.
📊
Temel Bulgular & Veri:The average age in the prednisolone group was 32±7.15 years (range: 28-40 years) and it was 34±.2 years (range: 30-42 years) in patients who did not receive treatment.
💡
Sonuç & Katkı:There was no statistically significant difference between the groups in the RNLF evaluation (p>0.05).Conclusion: Treatment with IV prednisolone had no distinct effect on RNFL
🔬Tür:Literatür & Derleme Çalışması
📍Kapsam:Genişletilmiş Akademik Örneklem
⚙️Değişkenler:Alan Parametreleri
Abstract
Objectives: The aim of this study was to investigate the potential impact of intravenous (IV) prednisolone treatment on the retinal nerve fiber layer (RNFL) in multiple sclerosis (MS) patients with optic neuritis (ON).Methods: The demographic features, systemic illnesses, laboratory results, ophthalmological examination findings and RNFL measurements of 28 MS patients who had IV prednisolone treatment for ON and of 24 MS patients with ON that was not treated were retrieved and reviewed retrospectively.Results: Of the 52 patients included in the study, 31 were women and 21 were men. The average age in the prednisolone group was 32±7.15 years (range: 28-40 years) and it was 34±.2 years (range: 30-42 years) in patients who did not receive treatment. The initial RNFL in the treatment group was 116.81±5.41μm and it was 78.13±3.94 μm at the third month, while it was 118.2±6.07 μm initially and 80.09±5.18 μm at the third month in the untreated group. There was no statistically significant difference between the groups in the RNLF evaluation (p>0.05).Conclusion: Treatment with IV prednisolone had no distinct effect on RNFL
🔖
Bu Makaleye Atıf Yap
TELEK, H. H., KADERLİ, A., BALTA, Ö., SUNGUR, G., YAKIN, M., HAZIROLAN, D., OZDEMİR, E. S., ALTIPARMAK, U. E., ÖRNEK, F. (2017). The Effect of Intravenous Prednisolone Treatment on the Retinal Nerve Fiber Layer in Multiple Sclerosis Patients with Optic Neuritis. BEYOGLU EYE JOURNAL, Cilt: 2 - Sayı: 3, 96–100. https://ajindex.com/articles/148143
Beck RW, Trobe JD, Moke PS, Gal RL, Xing D, Bhatti MT, et al. High- and low-risk profiles for the development of multiple sclerosis within 10 years after optic neuritis: experience of the optic neuritis treatment trial. Arch Ophthalmol 2003;121:944–9
Lublin FD, Miller AE. Multiple sclerosis and other inflammatory demyelinating diseases of the central nervous system. In: Bradley WG, Daroff RB, Fenichel GM, Jankovic J, editors. Neurology in Clinical Practice. 5th ed. Philadelphia: Elseiver; 2008. p. 1584–614
Elbøl P, Work K. Retinal nerve fiber layer in multiple sclerosis. Acta Ophthalmol (Copenh) 1990;68:481–6
Mudun A. Optic Coherence Tomography in Neuro-Ophthalmological Diseases. Acıbadem University Health Sciences Magazine 2011;2:5–9
Current therapy in neurologic disease. In: Bakar M, çev ed. 7. baskı. Güneş Tıp Kitabevi; 2007. p. 185–208
Costello F, Coupland S, Hodge W, Lorello GR, Koroluk J, Pan YI, et al. Quantifying axonal loss after optic neuritis with optical coherence tomography. Ann Neurol 2006;59:963–9
Cheng H, Laron M, Schiffman JS, Tang RA, Frishman LJ. The relationship between visual field and retinal nerve fiber layer measurements in patients with multiple sclerosis. Invest Ophthalmol Vis Sci 2007;48:5798–805
Pueyo V, Martin J, Fernandez J, Almarcegui C, Ara J, Egea C, et al. Axonal loss in the retinal nerve fiber layer in patients with multiple sclerosis. Mult Scler 2008;14:609–14
Van Stavern GP. Management of optic neuritis and multiple sclerosis. Curr Opin Ophthalmol 2001;12:400–7
Brusaferri F, Candelise L. Steroids for multiple sclerosis and optic neuritis: a meta-analysis of randomized controlled clinical trials. J Neurol 2000;247:435–42
Beck RW, Gal RL, Bhatti MT, Brodsky MC, Buckley EG, Chrousos GA, et al. Visual function more than 10 years after optic neuritis: experience of the optic neuritis treatment trial. Am J Ophthalmol 2004;137:77–83
Yau GS, Lee JW, Lau PP, Tam VT, Wong WW, Yuen CY. Prospective study on retinal nerve fibre layer thickness changes in isolated unilateral retrobulbar optic neuritis. ScientificWorldJournal 2013;2013:694613
Akyurekli O, Celebisoy N. Optic neuritis: Results with pulse methylprednisolone. J Neurol Sci Turk 2009;26:8–11
Vogt A. Herstellung eines gelbblauen Lichtfiltrates, in welchem die Makula centralis in vivo in gelber Farbe erscheint, die Nervenfasern der Netzhaut und andere feine Einzelheiten derselben sichtbar werden und der Grad der Gelb